Yıldız-Peköz Ayca, Ehrhardt Carsten
Department of Pharmaceutical Technology, Faculty of Pharmacy, İstanbul University, İstanbul 34116, Turkey.
School of Pharmacy and Pharmaceutical Sciences and Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.
Pharmaceutics. 2020 Sep 23;12(10):911. doi: 10.3390/pharmaceutics12100911.
Pulmonary drug delivery represents an attractive, non-invasive administration option. In addition to locally acting drugs, molecules that are intended to produce systemic effects can be delivered via the pulmonary route. Several factors need to be considered in the context of delivering drugs to or via the lungs-in addition to the drug itself, its formulation into an appropriate inhalable dosage form of sufficient stability is critical. It is also essential that this formulation is paired with a suitable inhaler device, which generates an aerosol of a particle/droplet size that ensures deposition in the desired region of the respiratory tract. Lastly, the patient's (patho-) physiology and inhalation manoeuvre are of importance. This Special Issue brings together recent advances in the areas of inhalation device testing, aerosol formulation development, use of in vitro and in silico models in pulmonary drug deposition and drug disposition studies, and pulmonary delivery of complex drugs, such as vaccines, antibiotics and peptides, to or via the lungs.
肺部给药是一种有吸引力的非侵入性给药方式。除了局部作用的药物外，旨在产生全身效应的分子也可以通过肺部途径给药。在将药物递送至肺部或通过肺部给药时，需要考虑几个因素——除了药物本身外，将其制成具有足够稳定性的合适可吸入剂型至关重要。同样重要的是，这种制剂要与合适的吸入装置配合使用，该装置能产生颗粒/液滴大小合适的气雾剂，以确保在呼吸道的期望区域沉积。最后，患者的（病理）生理学和吸入动作也很重要。本期特刊汇集了吸入装置测试、气雾剂制剂开发、体外和计算机模拟模型在肺部药物沉积和药物处置研究中的应用，以及疫苗、抗生素和肽等复杂药物向肺部或通过肺部给药等领域的最新进展。
